BioWorld

July 22, 2004

View Archived Issues

ImClone Reports Erbitux Sales Of $71.4M, Plans sBLA Filing

ImClone Systems Inc.'s stock fell 18.9 percent Wednesday even though the firm turned a profit on Erbitux sales and said it intends to request FDA approval of the drug in head and neck cancer. (BioWorld Today) Read More

Alexion Raises $77.5M To Fund Phase III Product Development

Read More

Seattle Genetics, Celera Join Up For Discovery Of Cancer Drugs

Read More

ConjuChem Raises C$25M In Notes Sale For DAC Compounds

Read More

Monitors Say Northfield Trial Of PolyHeme Can Continue

Read More

Other News To Note

Read More